Evidence map›Paper›PMID 37969845›Full record

ArticleJournal of gastrointestinal oncology2023

Identification of an optimal mutant allele frequency to detect activating

Bennett A Caughey, Kumiko Umemoto, Michelle F Green, Masafumi Ikeda, Melissa E Lowe, Makoto Ueno, Donna Niedzwiecki, Hiroya Taniguchi, Daniel J Walden, Yoshito Komatsu and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 2 countries.

Bennett A CaugheyDivision of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Kumiko UmemotoDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Michelle F GreenDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Melissa E LoweDuke Cancer Institute-Biostatistics Shared Resource, Durham, NC, USA.
Makoto UenoDepartment of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Donna NiedzwieckiDuke Cancer Institute-Biostatistics Shared Resource, Durham, NC, USA.
Hiroya TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Daniel J WaldenDivision of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
Yoshito KomatsuDepartment of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Rachel D'AnnaDuke Cancer Institute-Biostatistics Shared Resource and Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Taito EsakiDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Tadamichi DendaDivision of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Michael B DattoDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Hideaki BandoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tanios Bekaii-SaabDivision of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
John H StricklerDivision of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Duke Medical Center · USNational Cancer Center Hospital East · JPDuke Cancer InstituteAichi Cancer Center · JPChiba Cancer Center · JPHokkaido University Hospital · JPKanagawa Prefectural Hospital Organization · JPMayo Clinic in Florida · USSt. Marianna University School of Medicine · JPWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evaluation for activating mutations in Methods: Molecular and clinical data were obtained from the Duke Molecular Registry of Tumors and the SCRUM-Japan GOZILA study. Patients with CRC or PDAC and a Results: One hundred and thirty-five CRC and 30 PDAC cases with 198 total cfDNA assays met criteria. Greatest non- Conclusions: Non-

Indexed as

Cell-free DNA (cfDNA)colorectal cancer (CRC)pancreatic cancer

Identifiers

PMID37969845
PMCPMC10643595
OpenAlexW4388159482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.